<DOC>
	<DOCNO>NCT00419328</DOCNO>
	<brief_summary>The main objective trial explore safety biological activity NGR-hTNF . The safety establish clinical laboratory assessment . The biological activity evaluate DCE-MRI contrast medium .</brief_summary>
	<brief_title>A Modified Phase I Study NGR-hTNF Advanced Solid Tumors</brief_title>
	<detailed_description>This modify phase I Single arm , open , non randomize trial NGR-hTNF advance solid tumor definition optimal biological</detailed_description>
	<criteria>Patients &gt; 18 year old proven advance solid tumor amenable clinical improvement current standard treatment . Tumors recognize highly vascularize ( e.g . renal , colon thyroid head neck cancer ) , include . ECOG Performance status 0 2 Patients may prior therapy provide follow condition meet : Chemo , radio , hormonal immunotherapy : washout period 28 day Surgery : washout period 14 day Adequate baseline bone marrow , hepatic renal function , define follow : Neutrophils &gt; 1.5 x 10^9/L platelet &gt; 100 x 10^9/L Bilirubin &lt; 1.5 x ULN AST and/or ALT &lt; 2.5 x ULN absence liver metastasis AST and/or ALT &lt; 5 x ULN presence liver metastases Serum creatinine &lt; 1.5 x ULN Absence condition hypervolemia consequence ( e.g . increase stroke volume , elevate blood pressure ) haemodilution could represent risk patient ( reference appendix `` Technical data sheet human albumin '' ) Normal cardiac function absence uncontrolled hypertension Patients must give write informed consent participate study Concurrent anticancer therapy Patients may receive investigational agent study Clinical sign CNS involvement Patients active uncontrolled systemic disease/infections serious illness medical condition , incompatible protocol Known hypersensitivity/allergic reaction human albumin preparation excipients Any psychological , familial , sociological geographical condition potentially hamper compliance study protocol Pregnancy lactation . Patients male female reproductive potential ( i.e . menopausal le 1year surgically sterilize ) must practice effective contraceptive measure throughout study . Women childbearing potential must provide negative pregnancy test ( serum urine ) within 14 day prior registration .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>solid tumor NGR-hTNF</keyword>
</DOC>